BASKING RIDGE, N.J.--(BUSINESS WIRE)--VioQuest Pharmaceuticals (OTCBB: VOQP) today reported updated data from a Phase 1 dose escalation study evaluating Lenocta™ (sodium stibogluconate) in combination with interferon alpha-2b (IFN alpha-2b) in patients with various advanced solid tumors. Data from 21 patients were presented during an oral session titled “Developmental Therapeutics: Immunotherapy,” by Aung Naing, MD, assistant professor of medicine at the University of Texas M.D. Anderson Cancer Center, at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
